The SARS-CoV-2 pandemic has caused unprecedented global health and economic crises.
Several vaccine approaches and repurposed drugs are currently under evaluation for safety …

Despite substantial progress in confronting the global HIV-1 epidemic since its inception in
the 1980s, better approaches for both treatment and prevention will be necessary to end the …

Despite major advances in our understanding of the biology of HIV-1 infection, and
advances in antiretroviral therapy to treat the disease, there were 2.1 million new cases of …

An important class of HIV-1 broadly neutralizing antibodies, termed the VRC01 class, targets
the conserved CD4-binding site (CD4bs) of the envelope glycoprotein (Env). An engineered …

Anti-HIV broadly neutralizing antibodies (bnAbs) have revealed vaccine targets on the
virus's envelope (Env) protein and are themselves promising immunotherapies. The efficacy …

We have developed a method to introduce novel paratopes into the human antibody
repertoire by modifying the immunoglobulin (Ig) genes of mature B cells directly using …

Precisely defining how viral mutations affect HIV's sensitivity to antibodies is vital to develop
and evaluate vaccines and antibody immunotherapeutics. Despite great effort, a full map of …

In the last decade, over a dozen potent broadly neutralizing antibodies (bnAbs) to several
HIV envelope protein epitopes have been identified, and their in vitro neutralization profiles …

There is great interest in passive transfer of broadly neutralizing antibodies (bnAbs) and
engineered bispecific antibodies (Abs) for prevention of HIV-1 infections due to their in vitro …

Today, vaccinologists have come to understand that the hallmark of any protective immune
response is the antigen. However, it is not the whole antigen that dictates the immune …